Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats - PubMed (original) (raw)
Comparative Study
Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats
Marc Verleye et al. Physiol Behav. 2004.
Abstract
Anxiety disorders are often associated with autonomic symptoms, including heart palpitations, sweating, elevation of body temperature and alterations of gastrointestinal motility. Some of the alterations observed in animals exposed to stress are analogous to changes in a number of physiological and endocrine parameters observed in anxious patients. With the purpose to guide further clinical studies in subtypes of anxious patients, etifoxine, a nonbenzodiazepine anxiolytic compound, was evaluated in two rat models of anxiety with measures of physiological manifestations: stress-induced hyperthermia (SIH) and conditioned-fear-stress-induced freezing behavior and activation of colonic motility. The sequential handling of animals induced a rise in body temperature attenuated by etifoxine (50 mg/kg IP). The emotional stress induced by fear to receive electric foot shocks is accompanied by freezing behavior and an increase of the frequency of ceco-colonic spike bursts: both parameters were reduced by etifoxine (25-50 mg/kg IP), independently of changes in pain perception and memory-related processes. In response to a stressful event, the stimulation of the corticotropin-releasing hormone (CRH) system is probably involved in the observed modifications of body temperature and colonic motility. It is hypothesized that stress-induced CRH activation is attenuated by the enhancement of the inhibitory GABAergic system activity associated with etifoxine. These findings will guide future evaluation of etifoxine in the treatment of selected anxious patients with altered autonomic symptomatology.
Similar articles
- Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats.
Saito K, Kasai T, Nagura Y, Ito H, Kanazawa M, Fukudo S. Saito K, et al. Gastroenterology. 2005 Nov;129(5):1533-43. doi: 10.1053/j.gastro.2005.07.053. Gastroenterology. 2005. PMID: 16285953 - Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety.
Todorovic C, Radulovic J, Jahn O, Radulovic M, Sherrin T, Hippel C, Spiess J. Todorovic C, et al. Eur J Neurosci. 2007 Jun;25(11):3385-97. doi: 10.1111/j.1460-9568.2007.05592.x. Eur J Neurosci. 2007. PMID: 17553007 - Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats.
Ugale RR, Sharma AN, Kokare DM, Hirani K, Subhedar NK, Chopde CT. Ugale RR, et al. Brain Res. 2007 Dec 12;1184:193-201. doi: 10.1016/j.brainres.2007.09.041. Epub 2007 Sep 25. Brain Res. 2007. PMID: 17950705 - The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse.
Adriaan Bouwknecht J, Olivier B, Paylor RE. Adriaan Bouwknecht J, et al. Neurosci Biobehav Rev. 2007;31(1):41-59. doi: 10.1016/j.neubiorev.2006.02.002. Epub 2006 Apr 17. Neurosci Biobehav Rev. 2007. PMID: 16618509 Review. - Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm.
Vinkers CH, van Bogaert MJ, Klanker M, Korte SM, Oosting R, Hanania T, Hopkins SC, Olivier B, Groenink L. Vinkers CH, et al. Eur J Pharmacol. 2008 May 13;585(2-3):407-25. doi: 10.1016/j.ejphar.2008.02.097. Epub 2008 Mar 18. Eur J Pharmacol. 2008. PMID: 18420191 Review.
Cited by
- Differential effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment.
Brunner LM, Maurer F, Weber K, Weigl J, Milenkovic VM, Rupprecht R, Nothdurfter C, Mühlberger A. Brunner LM, et al. Psychopharmacology (Berl). 2022 Jul;239(7):2233-2244. doi: 10.1007/s00213-022-06111-x. Epub 2022 Mar 12. Psychopharmacology (Berl). 2022. PMID: 35278124 Free PMC article. - An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action.
Nuss P, Ferreri F, Bourin M. Nuss P, et al. Neuropsychiatr Dis Treat. 2019 Jul 3;15:1781-1795. doi: 10.2147/NDT.S200568. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 31308671 Free PMC article. Review. - Ameliorating Impact of Prophylactic Intranasal Oxytocin on Signs of Fear in a Rat Model of Traumatic Stress.
Renicker MD, Cysewski N, Palmer S, Nakonechnyy D, Keef A, Thomas M, Magori K, Daberkow DP. Renicker MD, et al. Front Behav Neurosci. 2018 May 28;12:105. doi: 10.3389/fnbeh.2018.00105. eCollection 2018. Front Behav Neurosci. 2018. PMID: 29892216 Free PMC article. - Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury.
Simon-O'Brien E, Gauthier D, Riban V, Verleye M. Simon-O'Brien E, et al. J Neuroinflammation. 2016 Aug 26;13(1):203. doi: 10.1186/s12974-016-0687-3. J Neuroinflammation. 2016. PMID: 27565146 Free PMC article. - The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.
do Rego JL, Vaudry D, Vaudry H. do Rego JL, et al. PLoS One. 2015 Mar 18;10(3):e0120473. doi: 10.1371/journal.pone.0120473. eCollection 2015. PLoS One. 2015. PMID: 25785994 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical